Palatin Targets the Next Generation of Rare Obesity Therapies After MC4R Validation (NASDAQ: PTN)

WSW, NY, September 28th, 2026, FinanceWireThe obesity market has been transformed by GLP-1 therapies, but the next phase of innovation is increasingly expanding beyond GLP-1 alone. One small biotechnology company positioned at the intersection of several of these trends is Palatin Technologies (Nas…